Synlogic Inc · OTC:SYBX

Synlogic — Q3 2020 Earnings Presentation

17 slides from Synlogic's earnings presentation, Nov 5, 2020

  1. Slide 1: Q3 Financial Results & Business Update

    © 2020 SYNLOGIC. QUARTERLY RESULTS. ALL RIGHTS RESERVED. | 1 © 2020 SYNLOGIC. ALL RIGHTS RESERVED. | 1 Bringing the Transformative Power of Synthetic Biology to Medicine Q3 Financial Results & Business Update 5 November 2020 Exhibit 99.3

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Opening Remarks

    © 2020 SYNLOGIC. QU©AR2T0E1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 33 Opening Remarks Dr. Aoife Brennan MB CHB President & CEO

  4. Slide 4: 3rd Quarter Highlights: Execution Across the Portfolio

    Rapidly progressed metabolic programs SYNB1618 in PKU Phase 2 SynPheny-1 study initiated IND for SYNB8802 in Enteric Hyperoxaluria opened and Phase 1 study initiated Metabolic Programs Immunomodulation in immunology and oncology SYNB1891 monotherapy continues to enroll: study update expected late 20

  5. Slide 5: Synlogic Entering Data Rich Period In The Clinic

    Synlogic Entering Data Rich Period In The Clinic Expected Milestone 2020 2021 early mid late early mid late SYNB1618 PKU Initiate Ph.2 study in PKU patients initiated Ph.2 Phe-lowering read-out SYNB8802 HOX Initiate IND-enabling studies completed Initiate Ph.1 study in HV and Patients initiated Ph.1

  6. Slide 6: Strong Cash Position With Runway Into 2022

    Strong Cash Position With Runway Into 2022 Balance Sheet (unaudited) 30 Sept 2020 30 June 2020 Cash, Cash Equivalents, and Short & Long Term Marketable Securities $102.0 M $109.1M Statement of Operations (unaudited) 30 Sept 2020 30 Sept 2019 R&D Expenses $10.5 M $10.6 M G&A Expenses $3.0 M $3.9 M Ne

  7. Slide 7: Progress in Metabolic Programs

    © 2020 SYNLOGIC. QUARTERLY RESULTS. ALL RIGHTS RESERVED. | 9 Progress in Metabolic Programs Dr. Richard Riese, MD, PhD Chief Medical Officer

  8. Slide 8: Phenylketonuria (PKU)

    Phenylketonuria (PKU) Emerging treatment options will continue to leave many patients behind SYNB1618 demonstrates potential to lower Phe in PKU patients Phase 2 Phe -lowering trial initiated

  9. Slide 9: Synlogic's Approach to Phenylketonuria (PKU)

    Synlogic’s Approach to Phenylketonuria (PKU) Julia, living with PKU SYNB1618 was able to consume Phe in healthy volunteers Synlogic has initiated a Phase 2 Study in PKU patients (SynPheny-1) PKU Program Status Synthetic Biotic Mechanism of Action Consume Phe in the GI Tract Reduce Phe in the blood

  10. Slide 10: SYNB1618 in the Clinic: Solid Oral HV Data Demonstrates Phe Lowering

    SYNB1618 in the Clinic: Solid Oral HV Data Demonstrates Phe Lowering D5-labeled Phe and biomarkers of strain activity measured at baseline and after treatment Finding: SYNB1618 consumes Phe in the GI tract based on biomarkers in a dose dependent manner SYNB1618 Mechanism Confirmed: Accessed D5-Phe T

  11. Slide 11: SynPheny-1 Phase 2 Proof of Concept Study in PKU

    SynPheny-1 Phase 2 Proof of Concept Study in PKU Dose 2 3e11 3 days Dose 1 1e11 Dose 3 1e12 Dose 4 2e12 7 days 2 days Diet run-in 6 days D5-Phe AUC Fasting Phe Fasting Phe 3 days D5-Phe AUC Demonstrate Phe Lowering in PKU Patients Plasma Phe lowering in fasted state at 1 x 1012 live cells over 7 day

  12. Slide 12: Patient-Centered Clinical Trial Design & Execution

    Dose ramp to improve tolerability & compliance Patient-Centered Clinical Trial Design & Execution Directly informed by patient feedback on executing trials in the COVID era Flexible design allowing home-based or office-based visits Rigorous & personalized diet control to ensure consistent Phe intake

  13. Slide 13: Enteric Hyperoxaluria

    Enteric Hyperoxaluria Enteric Hyperoxaluria results in significant kidney damage with no available treatment options SYNB8802 has the potential to meaningfully lower urinary oxalate levels SYNB8802 Phase 1 clinical study initiated ahead of schedule

  14. Slide 14: Synlogic's Approach to Enteric Hyperoxaluria

    Synlogic’s Approach to Enteric Hyperoxaluria SYNB8802 was able to consume oxalate in multiple animal models Synlogic has initiated a Phase 1 Study in healthy volunteers Enteric Hyperoxaluria Program Status Synthetic Biotic Mechanism of Action Consume Oxalate in the GI Tract Reduce Oxalate in the uri

  15. Slide 15: Enteric Hyperoxaluria: Phase 1 Design Provides PoC Opportunity

    Enteric Hyperoxaluria: Phase 1 Design Provides PoC Opportunity Roux-en-y gastric bypass population provides opportunity to demonstrate urinary oxalate lowering in disease state Phase 1a Healthy Volunteers Multiple Ascending Dose High oxalate & low calcium diet run-in Primary: Safety & tolerability S

  16. Slide 16: Concluding Remarks

    © 2020 SYNLOGIC. QU©AR2TE1R9LYSYRNELSOUGLTICS.. AALLLL RRIIGGHHTTSS RREESSEERRVVEEDD.. || 1414 Concluding Remarks Dr. Aoife Brennan MD CHB President & CEO

  17. Slide 17: Available For Questions

    Available For Questions Aoife Brennan, MD CHB President & CEO Richard Riese, MD PhD CMO Gregg Beloff, JD MBA Interim CFO Antoine Awad, COO David Hava, PhD CSO

Synlogic — Q3 2020 Earnings Presentation on 6ix